Hereditary Cancer Panel denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Happens

Blue Cross Blue Shield plans sometimes deny hereditary cancer panel testing as "duplicate therapy" when records show a prior genetic test — often a single-gene test such as BRCA1/2 alone — was performed in the past. The plan's system flags the new multi-gene panel as redundant. In practice, a focused single-gene test and a comprehensive hereditary cancer panel are clinically distinct services: the prior test answered a narrow question, while the panel interrogates a broader set of genes relevant to the patient's personal or family history. The denial conflates different tests and is routinely overturned on appeal.

## Why This Is Appealable

A duplicate-therapy denial requires the plan to show that the same service, providing the same clinical information, was already rendered. If the prior test evaluated fewer genes than the requested panel, or was ordered for a different clinical indication, the services are not duplicates. Your ordering clinician's letter should make this distinction explicit. BCBS must provide a full-and-fair internal review, and if that fails, you have the right to independent external review under the ACA.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial notice (commonly 180 days). BCBS must respond within 30 days for standard pre-service requests.
• External review (ACA §2719): After final internal denial, you may request external review — generally within four months. An accredited independent review organization, not BCBS, makes the final coverage determination.
• Expedited review: Available when a treatment decision is urgent; turnaround is 72 hours.
• ERISA §503: For self-funded employer plans, the full-and-fair review requirement and federal court access apply after internal exhaustion.

## Documentation to Gather

1. Prior test records — the exact name, lab, date, and gene panel covered by the prior test, demonstrating it is a different, narrower test than the one now requested. 2. Ordering clinician's letter — explaining the clinical distinction between the prior test and the requested panel, and the specific clinical question the panel is intended to answer. 3. Personal and family history documentation — pedigree or clinical notes establishing why a broader panel is medically warranted now, even after a prior partial test. 4. BCBS published coverage policy for hereditary cancer genetic testing — obtained from the denial notice or BCBS's online medical policy library — and the applicable guideline organization's (e.g., NCCN) testing criteria for this patient's history. 5. Pathology or clinical notes supporting current diagnosis or risk indication.

## Criteria-Mapping Structure

Pull the exact duplicate-service definition from BCBS's coverage policy and the denial letter. In a two-column table, place each element of that definition on the left and the corresponding clinical fact — showing why this service does not meet the definition of a duplicate — on the right. The key argument is specificity: list the genes covered by the prior test versus the genes covered by the requested panel, then show the clinical relevance of the additional genes to this patient's history.